What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: Natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?

European Heart Journal

Volumn 27, Issue 2, 2006, Pages 193-200

  Galasko, Gavin I W ^a   Barnes, Sophie C ^b   Collinson, Paul ^b   Lahiri, Avijit ^a   Senior, Roxy ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Electrocardiogram; Hand held echocardiography; Left ventricular systolic dysfunction; Natriuretic peptides; Screening

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; COMMUNITY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEALTH CARE COST; HEART LEFT VENTRICLE OVERLOAD; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SCREENING TEST;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; CHILD; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDES; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 30344445105     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi559     Document Type: Article

References (28)

1. McMurray JJV, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19(Suppl. P):P9-P16.
2. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977-982.
3. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361:1843-1848.
4. The National Collaborating Centre for Chronic Conditions. Chronic heart failure. National clinical guideline for diagnosis and management in primary and secondary care 2003; NICE Guideline no. 5. Royal College of Physicians of London.
5. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-321.
6. McMurray JV, McDonagh TA, Davie AP, Cleland JGF, Francis CM, Morrison C. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998:19:842-846.
7. Senior R, Galasko G, Mayet J, McMurrary J. Screening for left ventricular dysfunction in the community: role of hand-held echocardiography and serum brain naturetic peptides. Heart 2003;89(suppl 3):iii24-28.
8. Petrie MC, Hogg K, Caruana L, McMurray JJV. Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction? Heart 2004;90:511-517.
9. Mosterd A, de Bruijne MC, Hoes AW, Deckers JW, Hofman A, Grobbee DE. Usefulness of echocardiography in detecting left ventricular dysfunction in population-based studies (The Rotterdam Study). Am J Cardiol 1997;79:103-104.
10. Galasko GIW, Lahiri A, Senior R. Portable echocardiography: an innovative tool in screening for cardiac abnormalities in the community. Eur J Echocardiogr 2003;4:119-127.
11. Khunti K, Squire I, Abrams KR, Sutton AJ. Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. Eur J Heart Fail 2004;6:571-576.
12. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
13. Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, Trawinski J, Boesgaard S, Aldershvile J. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic dysfunction. Heart 2003;89:150-154.
14. Galasko GIW, Senior R, Lahiri A. Ethnic differences in the prevalence and aetiology of left ventricular systolic dysfunction in the community - The Harrow Heart Failure Watch. Heart 2004, in press.
15. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-186.
16. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
17. Task force for the diagnosis and treatment of chronic heart failure; European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Task force report. Eur Heart J 2001;22:1527-1560.
18. European study group on diastolic heart failure. How to diagnose diastolic heart failure. Working group report. Eur Heart J 1998;19:990-1003.
19. http://www.trends-in-medicine.com/April2003/ACCdevices043p.pdf (January 2005)
20. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322.
21. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-982.
22. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-120.
23. Greaves K, Jeetley P, Hickman M, Dwivedi G, Sabharwal N, Lim T, Janardhanan R, Senior R. The use of hand carried ultrasound in the hospital setting: A cost effective analysis. J Am Soc Echocardiogr 2005;18:620-625.
24. Ng LL, Loke I, Davies JE, Khunti K, Stone M, Abrams KR, Chin DT, Squire IB. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 2003;5:775-782.
25. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide to detect preclinical systolic or diastolic dysfunction. Circulation 2004;109:3176-3181.
26. Caruana L, Petrie MC, Davie AP, McMurray JJV. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from 'diastolic heart failure' or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215-218.
27. Michel BC, Remme WJ, Kingma JH, Kragten JA, van Nieuwenhuizen R, van Hout BA. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. Eur Heart J 1996;17:731-740.
28. Glick H, Cook J, Kinosian B, Pitt B, Bourassa MG, Pouleur H, Gerth W. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail 1995;1:371-380.